Company Overview of SciFluor Life Sciences, LLC
SciFluor Life Sciences, LLC, a drug discovery company, develops a portfolio of therapeutics to treat various diseases. Its pipeline includes small molecule compounds in a range of disease and therapeutic categories, including neurology, ophthalmology, fibrosis, and inflammation. The company provides SF0166, a small molecule integrin antagonist to treat retinal disease, including age-related macular degeneration and diabetic macular edema through topical administration to the eye. It also offers SF0034, a KCNQ2/3 activator for suppressing neuronal hyperexcitability that is an anti-epileptic drug for treating patients with partial-onset epilepsy. The company was founded in 2011 and is based in...
300 Technology Square
Cambridge, MA 02139
Founded in 2011
Key Executives for SciFluor Life Sciences, LLC
Chief Executive Officer, Director and Senior Vice President At Allied Minds
Founder and Chief Scientific Advisor
Founder and Director of Chemistry
Vice President of Business Development
Vice President and General Manager of Imaging
Compensation as of Fiscal Year 2016.
SciFluor Life Sciences, LLC Key Developments
SciFluor Life Sciences, LLC Enters Clinical Trial Stage for Novel Treatment for Retinal Diseases
Aug 1 16
SciFluor Life Sciences Inc. announced that the investigational new drug application to the Food and Drug Administration is now in effect for SF0166 Topical Ophthalmic Solution (SF0166). This enables the company to initiate clinical testing of SF0166 in both wet Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME) patients. AMD and DME patients are typically treated by regular injections to the back of the eye. SF0166 will be administered in the form of eye drops, and is intended to replace these monthly injections. If successful, this would represent a major advance in the treatment of these diseases, which represents in excess of $8 billion in annual revenue. Clinical Study SF0166-C-001 is designed to be a multi-center, randomized Phase I/II trial in the United States to evaluate the safety and preliminary efficacy of SF0166 for the treatment of patients with DME. A separate multi-center, randomized, Phase I/II trial of SF0166 is planned for patients with neovascular AMD. The trials each are intended to have two dose groups of up to 20 patients with an aim to collect safety and tolerability data as well as to record changes in retinal thickness. In preclinical models, SF0166 has been shown to distribute to the back of the eye in therapeutically-effective amounts. The development of topically administered treatments for retinal diseases has long been considered an enormous challenge by the scientific and medical communities. This is largely because clinically relevant amounts of any given drug need to reach the retina and be retained for an appropriate period of time to exert a therapeutic effect. To date, no topically administered drug has been approved for the treatment of either wet AMD or DME.
SciFluor Life Sciences Names William Koster as Chairman of the Board
Apr 22 15
SciFluor Life Sciences named William Koster, PhD, a seasoned executive in drug discovery research and early clinical development, as Chairman of the Board. Koster previously served as President and Chief Executive Officer of Neurogen Corp. He also spent 30 years with Bristol-Myers Squibb Co. in various roles that included Senior Vice President overseeing worldwide drug discovery research and early clinical development through Phase 2a.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries